Kiniksa raises ARCALYST FY2023 guidance; Q1 revenue $48.3M, net loss narrows

Kiniksa Pharmaceuticals International, plc

2023-Q1 EPS reported -$0.18 revenue$48,345,000

ARCALYST Q1 net product revenue $42.7M; FY2023 guidance raised to $200-215M (~69% YoY growth at midpoint).
Net loss improved to $12.3M from $25.2M YoY; total revenue $48.3M vs $32.2M.
Cash & short-term investments $187.5M, no debt; cash runway now expected into at least 2026.
Final cohort of KPL-404 Phase 2 RA trial enrolling; data expected 1H 2024.
Over 1,000 prescribers written ARCALYST scripts since launch; payer approval rate >90%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kiniksa Pharmaceuticals International, plc reported first quarter 2023 results: revenue $48.3 million, net income $12.3 million. Guidance raised.

Period: first quarter 2023
Revenue: $48.3 million
Net income: $12.3 million
Guidance: raised
Result: reported results

Exact text from the filing

diseases where the granulocyte macrophage colony stimulating factor (GM-CSF) mechanism has been implicated. Financial Results · Total revenue for the first quarter of 2023 was $48.3 million, compared to $32.2 million for the first quarter of 2022. - Total revenue for the first quarter of 2023 included $42.7 million in ARCALYST net product revenue and $5.7 million in

View on SEC.gov

Browse all earnings releases →

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001104659-23-054807

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.